CELL LINES
Contributor Information
- Name Jeffrey Schlom, PhD
- Institute National Cancer Institute
- Primary citation Vandeveer et al. Cancer Immunol Res. 2016 May, 4(5):452-62. PMID: 26921031
Tool Details
- Tool name: MB49-luc Cell Line
- Alternate names: MB49-luciferase, MB49-luc, MB49luc
- Tool type: Cell Line
- Parental cell line: MB49 Cell Line
- Organism: Mouse
- Tissue: Bladder
- Gender: Male
- Cancer type: Genitourinary cancer
- Morphology: Epithelial cells
- Growth properties: Adherent
- Model: Tumourigenic line
- CRISPR: No
- Conditional: No
- Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
-
Description: MB49-luc cell line is an aggressive, bioluminescent orthotopic bladder cancer model. This model is a luminescent derivative of MB49, a murine transitional cell bladder carcinoma line.
The parental MB49 forms tumours when injected subcutaneously or orthotopically into mouse bladders and provides an opportunity to study the immune-related events involved in the use of immune cell checkpoint inhibitors for the treatment of carcinoma in situ and nonmuscle tissues.
MB49-luc cell line was used to study the antitumor effects of avelumab, an antibody to the programmed death-1 receptor (PD-L1). The bioluminescence also forms a readout for tumour take, growth and reduction.
MB49-luc murine tumour cells form multifocal tumours on the mucosal wall of the bladder reminiscent of nonmuscle invasive, non-metastatic urothelial carcinomas.
MB49-luc bladder tumours are highly positive for the expression of PD-L1 and respond to avelumab administration inducing significant antitumor effects (P<0.05). These antitumor effects were more dependent on the presence of CD4 than CD8 T cells, as determined by in vivo immune cell depletions.
Preclinical studies with this cellular model may provide the rationale for localized bladder cancer clinical studies that combine immune cell checkpoint inhibitors with other forms of immunotherapy, chemotherapy, radiotherapy, and small molecule inhibitors - Research area: Cancer
- Production details: Parental MB49 cells transfected with a pSELECT-zeo-LucSh plasmid using Lipofectamine (InvivoGen) for luciferase expression detected by in vivo imaging
- For Research Use Only
Target Details
- Target: PD-1, the programmed death-1 receptor
- Target background: The programmed death-1 (PD-1) receptor is a checkpoint inhibitor, that interacts with distinct ligands, PD-L1 (B7-H1, CD274). PD-L1 is expressed on a wide variety of human and mouse tumour cells and some immune cell populations
Application Details
- Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
- Application notes: Identification host antitumor immune mechanisms and evaluation combinations of immune-based therapies for carcinoma in situ and non–muscle invasive, non-metastatic urothelial carcinoma
Handling
- Growth medium: Dulbeccos Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal bovine serum supplemented with 1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, and penicillin/streptomycin (100 U/mL)
- Temperature: 37C
- Atmosphere: 5%CO2
- Storage conditions: Liquid Nitrogen
- Shipping conditions: Dry Ice
- Mycoplasma free: Yes
- Biosafety level: 1
Documentation
Related Tools
References
- • Vandeveer et al. Cancer Immunol Res. 2016 May, 4(5):452-62. PMID: 26921031
.svg)
Availability: 
.svg)
.svg)
